

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

Meral Beksac,¹ Guldane Cengiz Seval,¹ Nicholas Kanellias,² Daniel Coriu,³ Laura Rosiñol,⁴ Gulsum Ozet,⁵ Vesselina Goranova-Marinova,⁶ Ali Unal,⁷ Jelena Bila,⁸ Hayri Ozsan,⁹ Arben Ivanaj,¹⁰ Lejla Ibricevic Balić,¹¹ Efstathios Kastritis,² Joan Bladé,⁴ Meletios Athanasios Dimopoulos²

¹Department of Hematology, School of Medicine, Ankara University, Ankara, Turkey; ²Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; ³University of Medicine and Pharmacy "Carol Davila", Fundeni Clinical Institute, Bucharest, Romania; ⁴Hospital Clinic, IDIBAPS, Barcelona, Spain; ⁵Clinic of Hematology, Ankara Numune Education and Research Hospital, Ankara, Turkey; ⁶University Hospital "Sv. Georgi" and Medical University Plovdiv, Plovdiv, Bulgaria; ⁷Department of Hematology, School of Medicine, Erciyes University, Kayseri, Turkey; ⁸Faculty of Medicine, University of Belgrade, Belgrade, Serbia; ⁹Department of Hematology, School of Medicine, Dokuz Eylül University, Izmir, Turkey; ¹⁰University of Medicine Tirana, Tirana, Albania and ¹¹Clinical Center of Sarajevo University, Sarajevo, Bosnia and Herzegovina

Published in Haematologica 2020;105(1):201-208.

doi:10.3324/haematol.2020.278272

©2021 Ferrata Storti Foundation

We have noticed an error in the progression-free survival of patients with extramedullary plasmacytoma in our article published in Haematologica in January 2020 (doi: HAEMATOL/2019/219295).

The following sentence in the abstract:

“Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 13.6 months and overall survival of 11.4 months.”

Should be replaced by:

“Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 9.1 months and overall survival of 11.4 months.”

Likewise, on page 205, the following sentence:

“However, if diagnosed at relapse, PFS and OS were 13.6 months and 11.4 months for EMP compared to 20.9 months ($P=0.249$) and 39.8 months ($P=0.093$) for PO, respectively (Table 2 and Figure 1).”

Should be replaced by:

“However, if diagnosed at relapse, PFS and OS were 9.1 months and 11.4 months for EMP compared to 20.9 months ($P=0.249$) and 39.8 months ($P=0.093$) for PO, respectively (Table 2 and Figure 1).”

The error was also present in Table 2.
The corrected Table 2 is shown below.

Table 2. Comparison of response, survival outcomes of extramedullary plasmacytomas (EMP) or paraosseous (PO) patients either at diagnosis or at relapse.

	CR (%)	PFS (mos)	OS (mos)
EMP			
diagnosis (n=92)	19.3	38.9 (95% CI: 23.6-54.2)	46.5 (95% CI: 25.5-67.5)
relapse (n=84)	9	9.1 (95% CI: 11.6-15.6)	11.4 (95% CI: *6-16.2)
PO			
diagnosis (n=38)	34.2	51.7 (95% CI: 13.5-89.9)	NR
relapse (n=12)	54.5	20.9 (95% CI: 10.3-31.5)	39.8 (95% CI: 12.7-66.9)

Note: P-values for comparisons between EMP diagnosis and relapse: CR (P=0.034), PFS (P<0.001), OS (P=0.002). P-values for comparisons between PO diagnosis and relapse: CR (P=0.001), PFS (P=0.005), OS (P<0.001).

CR: complete remission; PFS: progression-free survival; OS: overall survival; n: number.